On Dec. 8, the FDA issued an emergency use authorization (EUA) for the use of AstraZeneca’s monoclonal antibody cocktail Evusheld (tixagevimab plus cilgavimab) for prophylactic use in currently uninfected people with compromised immune systems or with vaccine allergies that would prevent their being vaccinated against Covid.
The two antibodies in the cocktail are expected to provide around six months of protection. They act the same way as antibodies produced by the body itself: by attaching to areas on SARS-CoV-2’s spike protein and preventing the virus from entering and infecting cells.
